Remedy Pharmaceuticals Receives FDA Fast Track Designation

June 08, 2016 – Remedy Pharmaceuticals Receives FDA Fast Track Designation for CIRARA™

Remedy Pharmaceuticals, a privately-held pharmaceutical company focused on bringing life-saving hospital-based treatment to people affected by central nervous system (CNS) related edema, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its investigational drug, CIRARA, for the treatment of Large Hemispheric Infarctions (LHI).

Press Release